Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 3;5(10):e2238961.
doi: 10.1001/jamanetworkopen.2022.38961.

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

Lindsay R Hammons  1 , Aniko Szabo  1 , Abhishek Janardan  1 , Binod Dhakal  1 , Saurabh Chhabra  1 , Anita D'Souza  1 , Meera Mohan  1
Affiliations

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

Lindsay R Hammons et al. JAMA Netw Open. .
No abstract available

Plain language summary

This case series describes the kinetics of humoral deficiency in patients with relapsed refractory multiple myeloma treated with bispecific antibodies, the infectious complications, and response to COVID-19 immunization.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Dhakal reported consulting for Janssen Pharmaceuticals and Karyopharm Therapeutics Inc and serving on the advisory boards of Sanofi, Amgen Inc, Natera, and Arcellx, Inc, outside the submitted work. Dr D’Souza reported serving on clinical trial advisory boards for Janssen Pharmaceuticals and Prothena Corporation PLC, performing clinical trials for Teneobio, Inc, Regeneron Pharmaceuticals, Inc, and Caelum, and serving on the advisory boards of Bristol-Myers Squibb Company, Caelum, and Pfizer Inc outside the submitted work. Dr Mohan reported receiving institutional research funding from Takeda Pharmaceutical Company Limited, Novartis AG, Celgene/Bristol-Myers Squibb Company, and GSK PLC outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Kinetics of Humoral Deficiency in Relapsed Refractory Multiple Myeloma After Treatment With Bispecific Antibodies
A, Mean cumulative number of infections over time. Dotted lines indicate SDs. B, Plot of immunoglobulin levels within at-risk periods with a locally linear smoother curve. The dotted line shows the lower limit of detection. C, Swimmer plot representing each patient 1 time only (n = 42).
See this image and copyright information in PMC

References

    1. Lancman G, Richter J, Chari A. Bispecifics, trispecifics, and other novel immune treatments in myeloma. Hematology Am Soc Hematol Educ Program. 2020;2020(1):264-271. doi:10.1182/hematology.2020000110 - DOI - PMC - PubMed
    1. Usmani SZ, Garfall AL, van de Donk NWCJ, et al. . Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665-674. doi:10.1016/S0140-6736(21)01338-6 - DOI - PubMed
    1. Kambhampati S, Sheng Y, Huang CY, et al. . Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022;6(7):2045-2054. doi:10.1182/bloodadvances.2020004079 - DOI - PMC - PubMed
    1. Mohan M, Nagavally S, Dhakal B, et al. . Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022;6(8):2466-2470. doi:10.1182/bloodadvances.2021006178 - DOI - PMC - PubMed
    1. Wang Y, Li C, Xia J, et al. . Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 2021;5(23):5290-5299. doi:10.1182/bloodadvances.2021004603 - DOI - PMC - PubMed

Substances